Company Filing History:
Years Active: 2016-2019
Title: The Innovative Contributions of Andrew Naylor
Introduction
Andrew Naylor is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of microparticles for drug delivery. With a total of 2 patents to his name, Naylor's work is characterized by its innovative approach to formulating and preparing biologically active materials.
Latest Patents
Naylor's latest patents include a formulation of microparticles comprising gonadotropin-releasing hormone (GnRH) made by a process known as PGSS. This pharmaceutical formulation features a solid matrix of biodegradable polymers that includes a pharmaceutically active substance distributed homogeneously within the matrix. The active substance can be a GnRH agonist or antagonist, showcasing Naylor's focus on advancing therapeutic options. Another patent details a process for preparing microparticles that involve a biologically active material and a polymer, achieving a mean particle size of 10 to 500 micrometers. This process utilizes supercritical fluid technology to create microparticles that are essential for effective drug delivery.
Career Highlights
Throughout his career, Andrew Naylor has worked with prominent companies in the pharmaceutical industry, including Ferring B.V. and Critical Pharmaceuticals Limited. His experience in these organizations has allowed him to refine his expertise in drug formulation and delivery systems.
Collaborations
Naylor has collaborated with several professionals in his field, including Gregoire Charles Joseph Schwach and Lars Schiefelbein. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Andrew Naylor's innovative work in the pharmaceutical sector, particularly in the formulation of microparticles, highlights his significant contributions to drug delivery systems. His patents reflect a commitment to improving therapeutic options for patients.